TerraPower Isotopes distributes first of Actinium-225 samples

31 January 2024

US-based TerraPower announced that the TerraPower Isotopes team has distributed the first samples of Actinium-225 to two pharmaceutical companies. The Actinium-225 will be used as a starting material by these companies for research and development of advanced, targeted cancer treatments and in drug trials involving targeted alpha therapy in multiple disease areas.

“With this first round of samples, we are expanding the availability of this rare isotope, bringing the medical community closer to commercial sales of Actinium-225 and increasing widespread access for patients,” said TerraPower Isotopes President Scott Claunch. “Interest in Actinium-225 is high, and current capacity is short of drug development or commercialization requirements, which limits drug trials. Today marks the next step toward meeting global demand.”

Image courtesy of TerraPower

Privacy Policy
We have updated our privacy policy. In the latest update it explains what cookies are and how we use them on our site. To learn more about cookies and their benefits, please view our privacy policy. Please be aware that parts of this site will not function correctly if you disable cookies. By continuing to use this site, you consent to our use of cookies in accordance with our privacy policy unless you have disabled them.